Password reminder
Contact the editor Visit NeuroNews Twitter feed Visit NeuroNews Facebook page

Including stroke severity in risk models associated with improved prediction of risk of death

Monday, 23 Jul 2012 17:23

Adding stroke severity to a hospital 30-day mortality model based on claims data for Medicare beneficiaries with acute ischaemic stroke was associated with improvement in predicting the risk of death at 30 days and changes in performance ranking regarding mortality for a considerable proportion of hospitals, according to a study published by Gregg C Fonarow, University of California, Los Angeles, USA, and colleagues. 

The study is published in the 18 July issue of the Journal of the American Medical Association (JAMA).

“Increasing attention has been given to defining the quality and value of health care through reporting of process and outcome measures. National quality profiling efforts have begun to report hospital-level performance for Medicare beneficiaries, including 30-day mortality rates, for common medical conditions, including acute myocardial infarction, heart failure, and community-acquired pneumonia,” according to background information in the article. Stroke is among the leading causes of death, disability, hospitalisations, and health care expenditures in the United States. “There is increasing interest in reporting risk-standardised outcomes for Medicare beneficiaries hospitalised with acute ischaemic stroke, but whether it is necessary to include adjustment for initial stroke severity has not been well studied.”

Fonarow and colleagues conducted a study to evaluate the degree to which hospital outcome ratings and the ability to predict 30-day mortality are altered after including initial stroke severity in a claims-based risk model for hospital 30-day mortality for acute ischaemic stroke. For the study, data were analysed from 782 Get With The Guidelines-Stroke participating hospitals on 127,950 fee-for-service Medicare beneficiaries with ischaemic stroke. The patients had a score documented for the National Institutes of Health Stroke Scale (NIHSS, a 15-item neurological examination scale with scores from 0 to 42, with higher scores indicating more severe stroke) between April 2003 and December 2009.

The median (midpoint) age was 80 years, 57% were women, and 86% were white. Performance of claims-based hospital mortality risk models with and without inclusion of NIHSS scores for 30-day mortality was evaluated and hospital rankings from both models were compared. The NIHSS median score in this overall population was 5, and the median hospital-level NIHSS score was 5.

There were 18,186 deaths (14.5%) within the first 30 days, including 7,430 deaths during the index hospitalisation (in-hospital mortality, 5.8%). The median hospital-level 30-day mortality rate was 14.5%. The researchers found that the hospital mortality model with NIHSS scores had significantly better discrimination than the model without. Also, other index scores demonstrated substantially more accurate classification of hospital 30-day mortality after the addition of NIHSS score to the claims model. The model with NIHSS exhibited better agreement between observed and predicted mortality rates.

Analysis of data indicated that more than 40% of hospitals identified in the top or bottom 5 per cent of hospital risk-adjusted mortality would have been reclassified into the middle mortality range using a model adjusting for NIHSS score compared with a model without NIHSS score adjustment. “Similarly, when considering the top 20% and bottom 20% ranked hospitals, close to one-third of hospitals would have been reclassified,” the authors write.

“These findings highlight the importance of including a valid specific measure of stroke severity in hospital risk models for mortality after acute ischaemic stroke for Medicare beneficiaries. Furthermore, this study suggests that inclusion of admission stroke severity may be essential for optimal ranking of hospital with respect to 30-day mortality.”

“As public reporting and value-based purchasing policies increase for outcome measures, it is important to recognise the effect that using models with less than ideal discrimination and calibration has on the ranking of hospitals and the lack of correlation among ranking by models that do and do not adjust for critical risk determinants,” the researchers write.

In an accompanying editorial, Tobias Kurth, University of Bordeaux, France, and Mitchell S V Elkind, Columbia University, New York, write that the results of this study “clearly highlight the importance of incorporating information on stroke severity when conducting health outcomes research in stroke.”

“Excluding this information will lead to incorrect ranking of hospital performance by failing to consider that hospitals care for different patient populations. The influence of stroke severity on these outcome measures, moreover, seems different from that of measures of severity in other conditions. For other cardiovascular diseases, risk adjustment using demographic characteristics and claims-derived comorbid conditions may sufficiently account for the underlying case mix. Ischaemic stroke is a much more heterogeneous condition than ischaemic heart disease and is characterised by multiple subtypes, etiologies, and diverse outcomes. The assumption that what is true of myocardial infarction is also true of stroke, therefore, is flawed, as the present data underscore. The particular characteristics of stroke have to be taken into consideration by clinicians, insurance companies, and policy makers when comparing disease-specific health outcomes.”

Add New Comment

Most popular

Better outcomes observed in MR CLEAN non-general anaesthesia subgroup in post-hoc analysis
Thursday, 02 Apr 2015
In a post-hoc analysis of the use of general anaesthesia in the MR CLEAN trial (Multicenter randomized clinical trial of endovascular treatment for acute ischemic stroke in the Netherlands) ... Better outcomes observed in MR CLEAN non-general anaesthesia subgroup in post-hoc analysis

Study suggests feasibility of Baby Trevo for treatment of distal cerebrovascular occlusions
Thursday, 14 May 2015
Diogo Haussen and colleagues (Emory University School of Medicine, Atlanta, USA) report that their initial data suggest that treatment of distal cerebrovascular occlusions with the Trevo XP ProVue 3x2... Study suggests feasibility of Baby Trevo for treatment of distal cerebrovascular occlusions

Evidence builds for endovascular treatment of acute ischaemic stroke
Friday, 17 Apr 2015
With the publication of two more stroke trials, the evidence in favour of endovascular treatment in patients with acute ischaemic stroke has reached new heights. Data from SWIFT PRIME and REVASCAT ... Evidence builds for endovascular treatment of acute ischaemic stroke


New day in acute ischaemic stroke therapy
Friday, 17 Apr 2015
The newest generation of trials for acute ischaemic stroke, including MR CLEAN, ESCAPE, EXTEND IA and SWIFT PRIME, appear to have ushered in a new era in stroke therapy. Now, Joseph Broderick (... New day in acute ischaemic stroke therapy

Flow diverter technology for intracranial aneurysms
Tuesday, 31 Mar 2015
Gabor Toth writes for NeuroNews about the flow diverters that are currently available and the ongoing clinical trials that could have the potential to extend the indications of flow diverter therapy ... Flow diverter technology for intracranial aneurysms


Robert E Harbaugh
Thursday, 14 May 2015
Robert E Harbaugh speaks to NeuroNews about how far neurosurgery has come, and as president of AANS ... Robert E Harbaugh

Joseph Broderick
Wednesday, 07 Jan 2015
Joseph Broderick speaks to NeuroNews about the future of neurology and his research, in particular, ... Joseph Broderick

Cardiac Rhythm News Vascular News Cardiovascular News Interventional News Spinal News NeuroNews
BIBA Medical BIBA MedTech Insights CX Symposium ilegx
Password Reminder

BIBA Medical, 526 Fulham Road, Fulham, London, SW6 5NR.
TEL: +44 (0)20 7736 8788 FAX: +44 (0)20 7736 8283 EMAIL: 
© BIBA Medical Ltd is a company registered in England and Wales with company number 2944429.
VAT registration number 730 6811 50.
Site Map | Terms and Conditions